IPSEN (OTCMKTS:IPSEY – Get Free Report)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $34.35, but opened at $36.80. IPSEN shares last traded at $36.80, with a volume of 580 shares changing hands.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Monday, November 3rd. BNP Paribas cut IPSEN to an “underperform” rating in a report on Wednesday, November 26th. Finally, UBS Group lowered IPSEN to a “neutral” rating in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold”.
Read Our Latest Stock Report on IPSEN
IPSEN Trading Up 7.1%
About IPSEN
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Read More
- Five stocks we like better than IPSEN
- A month before the crash
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- YDES Could Be 2026’s Biotech Breakthrough
- Trump Era Reset? Why Gold Could Explode to $6,000
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
